Q-omics provides the consensus-scored ZNF563 profile across patient tissues and cancer cell-line models. ZNF563 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZNF563 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, ZNF563 RNA expression shows 19,958 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, LIHC, and UVM as cancer lineages where ZNF563 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF563 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF563 survival associations across molecular data types. ZNF563 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF563 RNA expression–survival associations across cancer types. High ZNF563 expression shows unfavorable associations in KICH, LGG and UVM, but favorable associations in MESO, KIRC and LUAD. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZNF563 RNA expression.
This table summarizes ZNF563 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF563. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF563 shows lower tumor expression in THCA, KICH, UCEC and LUAD and higher tumor expression in LIHC and COAD. The LIHC box plot shows higher ZNF563 RNA expression in tumor versus normal tissue (log2 FC = +1.455, t-test p < 0.001).
This table shows molecular features associated with ZNF563 in patient tissues and cancer cell lines. In patient samples, ZNF563 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF563 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Lymphoma.
